Nexia Biotechnologies, Ltd.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nexia Biotechnologies, Ltd.
Philippines FDA Slashes Approval Timelines For Generic Drugs
The Philippines Food and Drug Administration is set to shorten the timeline for generic review and approval from 120 days to just 45 days, as part of efforts to register new generics and bring down prices.
Cipla Points To Large GLP-1 India Opportunity Amid Speculation On Lilly Deal
Cipla refers to the transformational potential of GLP-1s in India, a market with 100m-plus diabetics and rising obesity, amid plans for oral semaglutide and speculation on partnering possibilities. A recalibration in the firm’s specialty products thrust is also seen.
Cipla Points To Large GLP-1 India Opportunity Amid Speculation On Lilly Deal
Cipla refers to the transformational potential of GLP-1s in India, a market with 100m-plus diabetics and rising obesity, amid plans for oral semaglutide and speculation on partnering possibilities. A recalibration in the firm’s specialty products thrust is also seen.
Glenmark Seeks To Revive US Momentum After Earnings 'Aberration'
Glenmark hopes complex and respiratory products including a potential filing for generic Flovent pMDI can restore some lost sheen of its US business going forward, but a compliance comeback for its Monroe site may be pivotal to deliver material gains.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice